Literature DB >> 19345354

Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice.

Jitske de Vries-van der Weij1, Susanne Zadelaar, Karin Toet, Louis M Havekes, Teake Kooistra, Patrick C N Rensen.   

Abstract

OBJECTIVE: Cholesteryl ester transfer protein (CETP) adversely affects the plasma lipoprotein profile by increasing VLDL-cholesterol and decreasing HDL-cholesterol. The relative contribution of either of these changes to atherosclerosis development is not known. We investigated to what extent the increase in VLDL-cholesterol can explain the atherogenic action of human CETP expression in APOE*3-Leiden (E3L) mice, a model for human-like lipoprotein metabolism. METHODS AND
RESULTS: E3L mice and E3L.CETP mice were fed a low cholesterol (LC) diet, resulting in a 4-fold increased VLDL-cholesterol level as well as a 9-fold increased atherosclerotic lesion area in the aortic root in E3L.CETP mice compared to E3L-LC mice. E3L mice fed a high cholesterol (HC) diet to match the increased VLDL-cholesterol levels in E3L.CETP mice, displayed a similar atherosclerotic lesion area as observed in E3L.CETP mice. Hence, the CETP-induced raise in atherosclerosis can largely be explained by increased VLDL-cholesterol. Despite similar atherosclerosis development, E3L.CETP mice had lower HDL-cholesterol as compared to E3L-HC mice (-49%) indicating that the HDL-cholesterol lowering effect of CETP is unlikely to contribute to atherosclerosis development in this experimental setting. Remarkably, atherosclerotic lesions in CETP-expressing mice were enriched in collagen, suggesting a role of CETP or the diet in modifying lesion collagen content.
CONCLUSIONS: In this experimental setting, the proatherogenic effect of CETP is largely explained by increased VLDL-cholesterol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19345354     DOI: 10.1016/j.atherosclerosis.2009.02.038

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Animal models of atherosclerosis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

2.  siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.

Authors:  Marija Tadin-Strapps; Laurence B Peterson; Anne-Marie Cumiskey; Raymond L Rosa; Vivienne Halili Mendoza; Jose Castro-Perez; Oscar Puig; Liwen Zhang; Walter R Strapps; Satyasri Yendluri; Lori Andrews; Victoria Pickering; Julie Rice; Lily Luo; Zhu Chen; Samnang Tep; Brandon Ason; Elizabeth Polizzi Somers; Alan B Sachs; Steven R Bartz; Jenny Tian; Jayne Chin; Brian K Hubbard; Kenny K Wong; Lyndon J Mitnaul
Journal:  J Lipid Res       Date:  2011-03-11       Impact factor: 5.922

Review 3.  Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease.

Authors:  Christian Besler; Thomas F Lüscher; Ulf Landmesser
Journal:  EMBO Mol Med       Date:  2012-03-16       Impact factor: 12.137

4.  Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice.

Authors:  Chunxiu Hu; Heng Wei; Anita M van den Hoek; Mei Wang; Rob van der Heijden; Gerwin Spijksma; Theo H Reijmers; Jildau Bouwman; Suzan Wopereis; Louis M Havekes; Elwin Verheij; Thomas Hankemeier; Guowang Xu; Jan van der Greef
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

5.  Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice.

Authors:  Heng Wei; Chunxiu Hu; Mei Wang; Anita M van den Hoek; Theo H Reijmers; Suzan Wopereis; Jildau Bouwman; Raymond Ramaker; Henrie A A J Korthout; Marco Vennik; Thomas Hankemeier; Louis M Havekes; Renger F Witkamp; Elwin R Verheij; Guowang Xu; Jan van der Greef
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

6.  Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.

Authors:  Jeremy D Furtado; Giacomo Ruotolo; Stephen J Nicholls; Robert Dullea; Santos Carvajal-Gonzalez; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-12-23       Impact factor: 8.311

Review 7.  Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.

Authors:  Fabian Linden; Gabriele Domschke; Christian Erbel; Mohammadreza Akhavanpoor; Hugo A Katus; Christian A Gleissner
Journal:  Front Physiol       Date:  2014-11-21       Impact factor: 4.566

8.  Mice with chimeric livers are an improved model for human lipoprotein metabolism.

Authors:  Ewa C S Ellis; Willscott Edward Naugler; Scott Nauglers; Paolo Parini; Lisa-Mari Mörk; Carl Jorns; Helen Zemack; Anita Lövgren Sandblom; Ingemar Björkhem; Bo-Göran Ericzon; Elizabeth M Wilson; Stephen C Strom; Markus Grompe
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.